Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
Publication
, Conference
McDermott, JD; Subbiah, V; Beck, JT; Doi, T; Hirohashi, T; Ingram, K; Li, R; Abbruzzese, JL
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Start / End Page
TPS270 / TPS270
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
McDermott, J. D., Subbiah, V., Beck, J. T., Doi, T., Hirohashi, T., Ingram, K., … Abbruzzese, J. L. (2023). Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. TPS270–TPS270).
McDermott, Jessica Dreger, Vivek Subbiah, Joseph Thaddeus Beck, Toshihiko Doi, Tomoko Hirohashi, Kim Ingram, Ruifeng Li, and James L. Abbruzzese. “Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.” In JOURNAL OF CLINICAL ONCOLOGY, 41:TPS270–TPS270, 2023.
McDermott JD, Subbiah V, Beck JT, Doi T, Hirohashi T, Ingram K, et al. Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS270–TPS270.
McDermott, Jessica Dreger, et al. “Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. TPS270–TPS270.
McDermott JD, Subbiah V, Beck JT, Doi T, Hirohashi T, Ingram K, Li R, Abbruzzese JL. Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS270–TPS270.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Start / End Page
TPS270 / TPS270
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences